Do Symtuza and Genvoya Have the Same Ingredients?
No, Symtuza and Genvoya do not contain the same ingredients. Both are Gilead Sciences HIV-1 fixed-dose combination antiretrovirals, but they differ in one key component while sharing three.[1]
Symtuza includes:
- Elvitegravir (integrase strand transfer inhibitor)
- Cobicistat (pharmacokinetic enhancer)
- Emtricitabine (nucleoside reverse transcriptase inhibitor)
- Tenofovir alafenamide (nucleotide reverse transcriptase inhibitor)
- Darunavir (protease inhibitor)
Genvoya includes:
- Elvitegravir
- Cobicistat
- Emtricitabine
- Tenofovir alafenamide
The main difference is Symtuza's addition of darunavir, which targets HIV protease to prevent viral maturation, making Symtuza suitable for treatment-naive or experienced adults, while Genvoya lacks a protease inhibitor.[1][2]
Why the Ingredient Swap Between Tenofovir Forms?
Both use tenofovir alafenamide (TAF), a newer prodrug of tenofovir with lower plasma levels and better kidney/bone safety than tenofovir disoproxil fumarate (TDF) in older regimens like Stribild. This upgrade happened around 2015-2016 for both drugs.[2]
When Do Patents Expire for These Drugs?
Symtuza's key patents, including those on darunavir combinations, extend into the late 2020s to early 2030s. Genvoya's elvitegravir and TAF patents face challenges, with some expiring by 2029; check DrugPatentWatch.com for litigation updates and exact dates.[3]
How Do Symtuza and Genvoya Compare for Treatment?
| Aspect | Symtuza | Genvoya |
|--------|---------|---------|
| Pill Burden | 1 pill daily with food | 1 pill daily with food |
| For Treatment-Naive | Yes | Yes |
| For Virologically Suppressed | Yes (switch option) | Yes |
| Key Resistance | Darunavir barrier reduces failure risk | Relies on elvitegravir |
| Common Side Effects | Diarrhea, nausea, headache (darunavir-related) | Nausea, diarrhea, headache |
| Renal/Bone Monitoring | Less frequent due to TAF | Less frequent due to TAF |
Symtuza suits patients needing protease inhibitor activity or with elvitegravir resistance; Genvoya fits broader naive populations.[1][2]
What Patient Concerns Come Up Most?
Users report Symtuza's darunavir causing more GI issues or rash versus Genvoya's milder profile. Both carry lactic acidosis and renal risks, but TAF minimizes these compared to TDF regimens. Switching between them requires viral load checks.[2]
[1]: Gilead Sciences prescribing information for Symtuza and Genvoya (FDA labels, 2023).
[2]: NIH HIVinfo guidelines on antiretroviral regimens.
[3]: DrugPatentWatch.com (search Symtuza/Genvoya patents).